Sökning: onr:"20192875" >
Comparative immunog...
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years Results to month 12 from a randomized trial
-
Leung, Ting Fan (författare)
-
Liu, Anthony Pak-Yin (författare)
-
Lim, Fong Seng (författare)
-
visa fler...
-
Thollot, Franck (författare)
-
Oh, Helen May Lin (författare)
-
Lee, Bee Wah (författare)
-
Rombo, Lars (författare)
-
Tan, Ngiap Chuan (författare)
-
Rouzier, Roman (författare)
-
Friel, Damien (författare)
-
De Muynck, Benoit (författare)
-
De Simoni, Stephanie (författare)
-
Suryakiran, Pemmaraju (författare)
-
Hezareh, Marjan (författare)
-
Folschweiller, Nicolas (författare)
-
Thomas, Florence (författare)
-
Struyf, Frank (författare)
-
visa färre...
-
(utgivare)
- 2015
- 2015
- Engelska.
-
Ingår i: Human Vaccines & Immunotherapeutics. - 2164-5515. ; 11:7, 1689-1702
Abstract
Ämnesord
Stäng
- This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18(2D)) vs. 2 or 3 doses of the HPV-6/11/16/18 vaccine (HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D)) in healthy girls aged 9-14 y. Girls were randomized (1:1:1) to receive HPV-16/18(2D) at months (M) 0,6 (N = 359), HPV-6/11/16/18(2D) at M0,6 (N = 358) or HPV-6/11/16/18(3D) at M0,2,6 (N = 358). The primary objective was non-inferiority/superiority of HPV-16/18 antibodies by ELISA for HPV-16/18(2D) vs. HPV-6/11/16/18(2D) at M7 in the according-to-protocol immunogenicity cohort (ATP-I) and total vaccinated cohort, respectively. Secondary objectives included non-inferiority/superiority of HPV-16/18(2D) vs. HPV-6/11/16/18(3D) at M7, non-inferiority/superiority at M12, HPV-16/18 neutralizing antibodies, frequencies of T-cells/B-cells, reactogenicity and safety. Antibody responses at M7 for HPV-16/18(2D) were superior to those for HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D) (lower limit of 95% confidence interval for geometric mean titer ratio (GMR) was >1): HPV-16/18(2D)/HPV-6/11/16/18(2D) GMRs were 1.69 [1.49-1.91] for anti-HPV-16 and 4.52 [3.97-5.13] for anti-HPV-18; HPV-16/18(2D)/HPV-6/11/16/18(3D) GMRs were 1.72 [1.54-1.93] for anti-HPV-16 and 3.22 [2.82-3.68] for anti-HPV-18; p = 0.0001 for all comparisons. Non-inferiority/superiority was also demonstrated at M12. Among initially seronegative girls in the ATP-I, neutralizing antibody titers were at least 1.8-fold higher for HPV-16/18(2D) vs. HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D) at M7 and M12. Frequencies of HPV-16/18-specific T-cells and B-cells were in similar ranges between groups. Reactogenicity and safety were in line with the known profile of each vaccine. In conclusion, superior HPV-16/18 antibody responses were elicited by 2 doses of the HPV-16/18 AS04-adjuvanted vaccine compared with 2 or 3 doses of the HPV-6/11/16/18 vaccine in girls (9-14years).
Ämnesord
- Medical and Health Sciences (hsv)
- Basic Medicine (hsv)
- Immunology in the medical area (hsv)
- Medicin och hälsovetenskap (hsv)
- Medicinska grundvetenskaper (hsv)
- Immunologi inom det medicinska området (hsv)
- Medical and Health Sciences (hsv)
- Medical Biotechnology (hsv)
- Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) (hsv)
- Medicin och hälsovetenskap (hsv)
- Medicinsk bioteknologi (hsv)
- Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) (hsv)
Nyckelord
- administration schedule
- female adolescents
- immunogenicity
- human papillomavirus (HPV) vaccines
- safety
- 2D
- 2-dose
- 3D
- 3-dose
- AAHS
- aluminum hydroxyphosphate sulfate
- ANOVA
- analysis of variance
- AS04
- Adjuvant System containing 50 mu g 3-O-desacyl-4-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 mu g Al3+)
- ATP-I
- according-to-protocol immunogenicity cohort
- CI
- confidence interval
- CMI
- cell-mediated immunity
- ED50
- effective dose producing 50% response
- ELISA
- enzyme-linked immunosorbent assay
- ELISPOT
- enzyme-linked immunosorbent spot assay
- EU
- ELISA unit
- GMR
- geometric mean titer ratio
- GMT
- geometric mean antibody titer
- HPV
- human papillomavirus
- HPV-16
- 18(2D)
- 2-dose schedule of the HPV-16
- 18 vaccine
- HPV-6
- 11
- 16
- 2-dose schedule of the HPV-6
- 18(3D)
- 3-dose schedule of the HPV-6
- IFN
- interferon
- M
- month(s)
- IgG
- immunoglobulin G
- PBMC
- peripheral blood mononuclear cells
- PBNA
- pseudovirion-based neutralisation assay
- pIMD
- potential immune-mediated disease
- SAE
- serious adverse event
- TVC
- total vaccinated cohort
- VLP
- virus-like particle
- y
- year(s)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Leung, Ting Fan
-
Liu, Anthony Pak ...
-
Lim, Fong Seng
-
Thollot, Franck
-
Oh, Helen May Li ...
-
Lee, Bee Wah
-
visa fler...
-
Rombo, Lars
-
Tan, Ngiap Chuan
-
Rouzier, Roman
-
Friel, Damien
-
De Muynck, Benoi ...
-
De Simoni, Steph ...
-
Suryakiran, Pemm ...
-
Hezareh, Marjan
-
Folschweiller, N ...
-
Thomas, Florence
-
Struyf, Frank
-
visa färre...
- Av lärosätet
-
Swepub_uni:_t